Chip-based Oligonucleotide Synthesis Market Research: Reach USD 177 Million by 2031 at 23.6% CAGR

The global Chip-based Oligonucleotide Synthesis market is accelerating into a new phase of growth, driven by high-throughput DNA and RNA production for next-generation sequencing, gene editing, synthetic biology, and data storage. According to the recent report from QYResearch, the market is projected to grow from US$ 41 million in 2024 to US$ 177 million by 2031, achieving a compound annual growth rate of 23.6% between 2025 and 2031. Chip-based platforms, which leverage microarray and silicon technology, enable parallel synthesis of thousands to millions of oligonucleotides, offering unmatched speed, accuracy, and scalability for industrial and academic applications.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/sample/3370645



Leading Companies

Thermo Fisher
GenScript
LC Sciences
Twist Bioscience
Agilent Technologies
Evonetix
Dynegene Technologies
LC-Bio Technologies
Atantares
BGI Genomics



Applications

Scientific Research
Others



Classification by Technology

Photochemical Method
Electrochemical Method
Inkjet Printing Method



Latest Data & Market Outlook

· Global market value: US$ 41 million in 2024, forecast to reach US$ 177 million in 2031

· CAGR: 23.6% during 2025-2031

· Regional performance: North America leads in 2024, while Asia-Pacific is forecast to show the highest CAGR, with strong contributions from China, Japan, and South Korea

· Top players: Leading suppliers account for the majority of global revenue, with Thermo Fisher ranking first in 2024

· Market coverage: Historical data 2020-2024, forecasts 2025-2031, segmented by type, application, and geography

· Industry chain: Comprehensive analysis of upstream, midstream, and downstream distribution, with a focus on cost drivers and unmet demand



Recent Developments in 2024-2025

· Twist Bioscience launched Multiplexed Gene Fragments in 2024 and a high-throughput UDI adapter system in 2025. In May 2025, it spun off its DNA data storage division as Atlas Data Storage, with US$155 million in financing.

· Agilent Technologies enhanced its SurePrint Oligo Library Synthesis platform, offering long oligonucleotides up to ~230 nucleotides with HiFi quality and continuous 24/7 production capacity.

· Evonetix advanced its benchtop DNA synthesis chip, integrating thermal control to produce accurate, gene-length DNA directly in laboratories.

· Dynegene Technologies showcased ultra-long complex oligonucleotide synthesis capabilities in 2025, signaling Asia-Pacific's growing role in high-end DNA manufacturing.

· Thermo Fisher continued to update its Affymetrix Axiom genotyping arrays, supporting up to 200,000 markers per array, directly linked to chip-based oligo manufacturing.



Five Representative Products

Twist Bioscience - Oligo Pools

· Length range: 20-300 nucleotides

· Capacity: Over 1 million unique sequences per pool

· Error rate: Approximately 1 in 3000

· Use cases: CRISPR libraries, protein mutagenesis, target enrichment



Agilent Technologies - SurePrint Oligo Libraries (HiFi Pools)

· Length: Up to ~230 nucleotides

· High-fidelity chemistry with tight representation

· Applications: Gene assembly, protein design, large-scale CRISPR screening



LC Sciences - OligoMix®

· Scale: Thousands to tens of thousands of oligonucleotides per pool

· Length: Up to 150 nucleotides, with longer lengths available on request

· Applications: Barcode libraries, CRISPR gRNA design, capture probe generation



Thermo Fisher - Axiom Custom Genotyping Arrays

· Throughput: 96 or 384 arrays per plate

· Marker density: 90,000 to 200,000 per array

· Applications: Agrigenomics, human genetics, biomarker discovery



Dynegene Technologies - UCOS Oligo Libraries

· Focus: Ultra-long DNA synthesis and pooled oligonucleotide libraries

· Application: Gene assembly, antibody discovery, de novo genome synthesis



Verified Downstream Customers

Microsoft
Ginkgo Bioworks
Element Biosciences
Absci
xFOREST Therapeutics
Curio Genomics
Admera Health
Sampled
Western Digital
bitBiome
C2i Genomics
Astellas
MBC BioLabs



Market Trends 2025

Scaling Uniformity and Accuracy

Modern chip-based platforms now deliver oligo pools with hundreds of thousands to millions of unique sequences, maintaining high uniformity. Twist Bioscience reports that over 90% of sequences fall within 2.5× of the mean abundance, reducing dropout rates and improving experimental reliability. This directly benefits CRISPR screening and protein mutagenesis campaigns.



Longer Oligos and Multiplexed Fragments

Agilent and Twist have extended routine synthesis lengths to 230-300 nucleotides. Twist has also introduced multiplexed gene fragments up to 500 base pairs, enabling direct cloning and reducing downstream assembly steps. These advancements shorten design-to-validation timelines in both research and commercial applications.



DNA Data Storage Commercialization

The field has entered a commercialization phase. Twist Bioscience's spin-off, Atlas Data Storage, is now dedicated to developing DNA as a data medium, with significant financial backing. Microsoft and Western Digital continue to invest in DNA storage research, indicating that chip-based oligo synthesis will play a foundational role in scaling this new digital archive technology.



Benchtop DNA Synthesis Emergence

Companies such as Evonetix are pioneering benchtop DNA writing systems. By integrating thermal control on semiconductor chips, these platforms aim to decentralize synthesis, allowing laboratories to generate DNA constructs without outsourcing. This trend may reshape supply chains by offering localized, on-demand synthesis.



Integration with Sequencing Workflows

Chip-based synthesis is now tightly coupled with next-generation sequencing platforms. Twist has expanded collaborations with Element Biosciences, ensuring customers can seamlessly move from oligo pools to sequencing data. Service providers such as Sampled and Admera Health have adopted integrated workflows, lowering barriers for new adopters.



Sustainability and Transparency

Customers are beginning to request environmental accountability. Twist Bioscience has published sustainability data, including the carbon footprint of oligo production. As volumes grow, cost transparency and environmental metrics are becoming part of procurement processes, adding a new dimension to competition.

Therapeutic Pipeline Expansion

The boom in oligonucleotide-based therapeutics (ASOs, siRNAs, aptamers) continues to pull demand for chip-based oligos. While GMP production is distinct, early-stage discovery requires vast, accurate oligo libraries for validation and screening. This alignment of preclinical research with chip-based technologies is expanding the total addressable market.



Conclusion

The chip-based oligonucleotide synthesis market is entering a high-growth era characterized by technical innovation, strategic partnerships, and new application domains such as DNA data storage and benchtop gene synthesis. With a forecast CAGR of 23.6% through 2031, leading players like Thermo Fisher, Twist Bioscience, Agilent, and Evonetix are redefining the landscape with scalable, high-accuracy platforms. As downstream customers including Microsoft, Ginkgo Bioworks, and Element Biosciences continue to adopt these solutions, the sector is poised to become a cornerstone of biotechnology, digital storage, and precision medicine.



Request for Pre-Order Enquiry On This Report https://www.qyresearch.com/customize/3370645

About us:

QY Research has established close partnerships with over 71,000 global leading players. With more than 20,000 industry experts worldwide, we maintain a strong global network to efficiently gather insights and raw data.



Our 36-step verification system ensures the reliability and quality of our data. With over 2 million reports, we have become the world's largest market report vendor. Our global database spans more than 2,000 sources and covers data from most countries, including import and export details.



We have partners in over 160 countries, providing comprehensive coverage of both sales and research networks. A 90% client return rate and long-term cooperation with key partners demonstrate the high level of service and quality QY Research delivers.



More than 30 IPOs and over 5,000 global media outlets and major corporations have used our data, solidifying QY Research as a global leader in data supply. We are committed to delivering services that exceed both client and societal expectations.

Contact Us:

If you have any queries regarding this report or if you would like further information, please contact us:

QY Research Inc.

Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States

E-mail: global@qyresearch.com

Tel: 001-626-842-1666(US)

EN: https://www.qyresearch.com

JP: https://www.qyresearch.co.jp

This release was published on openPR.